Table 4. Association between selected characteristics and SeroProtection proportion (after S2) (n = 46).
| Crude | Multivariate model 1a | Multivariate model 2b | Multivariate model 3c | Multivariate model 4d | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Category | sR (%) | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | |
| Age | 60–83/36–59 | 44/48 | 0.83 (0.27–2.60) | 0.75 | 2.14 (0.42–10.8) | 0.36 | 1.98 (0.41–9.60) | 0.40 | 0.93 (0.28–3.11) | 0.91 | 2.02 (0.44–9.26) | 0.37 |
| Gender | Female/Male | 33/67 | 0.25 (0.07–0.86) | 0.03 | 0.48 (0.11–2.06) | 0.32 | ||||||
| Underlying disease Lymphoma Acute leukemia Myeloma |
+/− +/− +/− |
19/68 62/40 75/40 |
0.12 (0.03–0.46) 2.40 (0.65–8.86) 4.50 (0.81–25.2) |
0.01 0.19 0.09 |
0.09 (0.01–0.94) 0.66 (0.08–5.46) 0.78 (0.06–10.4) |
0.04 0.70 0.85 |
0.07 (0.01–0.76) 0.66 (0.08–5.27) 1.01 (0.08–12.2) |
0.03 0.69 1.00 |
0.10 (0.02–0.58) | 0.01 | ||
| Chemotherapy Steroid Immunosuppressive Agents Anticancer agents* Rituximab |
+/− +/− +/− |
37/57 40/47 25/56 0/58 |
0.44 (0.14–1.41) 0.77 (0.12–5.06) 0.26 (0.07–0.98) NA |
0.17 0.78 0.05 |
1.11 (0.20–6.08) 0.57 (0.06–5.51) 0.23 (0.04–1.43) |
0.91 0.63 0.12 |
0.69 (0.10–4.71) 0.88 (0.08–9.99) 0.96 (0.10–9.12) |
0.70 0.92 0.97 |
||||
Logistic regression model. CI: confidence interval; OR: odds ratio; aModel include age, sex, lymphoma, acute leukemia, and myeloma; bModel include age, lymphoma, acute leukemia and myeloma; cModel include age, steroid, immunosuppressive agents and anticancer agents; dModel include age, lymphoma and anticancer agents;*Anticancer agents does not include rituximab.